Use of Botulinum Toxin A (BoNT-A) in Detrusor External Sphincter Dyssynergia (DESD): A Systematic Review and Meta-analysis.
Adult
Anal Canal
Anus Diseases
/ drug therapy
Ataxia
/ drug therapy
Botulinum Toxins, Type A
/ therapeutic use
Clinical Trials as Topic
Female
Humans
Male
Middle Aged
Neuromuscular Agents
/ therapeutic use
Prospective Studies
Quality of Life
Retreatment
Retrospective Studies
Treatment Outcome
Urethra
/ drug effects
Journal
Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
06
12
2019
revised:
19
02
2020
accepted:
04
03
2020
pubmed:
22
3
2020
medline:
21
1
2022
entrez:
22
3
2020
Statut:
ppublish
Résumé
We performed a systematic review to examine the efficacy and outcomes of Botulinum Toxin A (BoNT-A) as the primary intervention strategy for patients with detrusor external sphincter dyssynergia. Eleven studies were included in the analysis (n = 353; 16% female, 84% male). BoNT-A was effective in 60%-78% of patients for reducing postvoid residual, mean detrusor pressure, detrusor leak point pressure, and mean urethral pressure 1 month after injection. Most patients required reinjection after an average of 4-9 months. BoNT-A was not associated with any significant adverse events, and may improve quality of life, as well as urodynamic parameters for detrusor external sphincter dyssynergia.
Identifiants
pubmed: 32197987
pii: S0090-4295(20)30273-9
doi: 10.1016/j.urology.2020.03.007
pii:
doi:
Substances chimiques
Neuromuscular Agents
0
Botulinum Toxins, Type A
EC 3.4.24.69
incobotulinumtoxinA
EC 3.4.24.69
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7-13Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.